

OIL CONSERVATION COMMISSION

Santa Fe, New Mexico

MISCELLANEOUS REPORTS ON WELLS

Submit this report in triplicate to the Oil Conservation Commission or its proper agent within ten days after the work specified is completed. It should be signed and sworn to before a notary public for reports on beginning drilling operations, results of shooting well, results of test of casing shut-off, result of plugging of well, and other important operations, even though the work was witnessed by an agent of the Commission. Reports on minor operations need not be signed and sworn to before a notary public. See additional instructions in the Rules and Regulations of the Commission.

Indicate nature of report by checking below:

REPORT ON BEGINNING DRILLING OPERATIONS		REPORT ON REPAIRING WELL	
REPORT ON RESULT OF SHOOTING OR CHEMICAL TREATMENT OF WELL	X	REPORT ON PULLING OR OTHERWISE ALTERING CASING	
REPORT ON RESULT OF TEST OF CASING SHUT-OFF		REPORT ON DEEPENING WELL	
REPORT ON RESULT OF PLUGGING OF WELL			

May 25, 1944 Artesia, New Mexico

Place

Date

OIL CONSERVATION COMMISSION,
SANTA FE, NEW MEXICO.

Gentlemen:

Following is a report on the work done and the results obtained under the heading noted above at the _____

O. H. Randel

State

Well No. 1

in the

Company or Operator

Lease

NW SW

of Sec. 19

T. 17

R. 31

N. M. P. M.,

~~Grayburg-Jackson~~ FREN

Field,

Eddy

County.

The dates of this work were as follows: May 16, 1944

Notice of intention to do the work was (was not) submitted on Form C-102 on _____ 19____

and approval of the proposed plan was (was not) obtained. (Cross out incorrect words.)

DETAILED ACCOUNT OF WORK DONE AND RESULTS OBTAINED

We shot the above well with 270 quarts of nitro-glycerine from 1910 to 1978. After shot we cleaned out to Total Depth (2002) and well flowed 65 BOPD

Witnessed by Clayton Mahres O. H. Randel Superintendent
Name Company Title

Subscribed and sworn before me this 27th

I hereby swear or affirm that the information given above is true and correct.

day of May, 1944

Name E. H. Randel

Position Owner

Representing O. H. Randel
Company or Operator

My commission expires Nov 19, 1946

Address 2015 N. Ochoa, El Paso, Texas

Remarks:

Ray. Garbrough
Name
Title

ИЗДАТЕЛЬСТВО ИМПЕРИАЛ, 1991

SECRET

1. The first step in the process is to identify the problem or issue that needs to be addressed. This involves gathering information and understanding the context of the problem.

Journal of Management Education 30(6)

[illegible]

1. *Pharmaceuticals* (1997) 10: 101-102.
 2. *Pharmaceuticals* (1997) 10: 103-104.
 3. *Pharmaceuticals* (1997) 10: 105-106.
 4. *Pharmaceuticals* (1997) 10: 107-108.
 5. *Pharmaceuticals* (1997) 10: 109-110.
 6. *Pharmaceuticals* (1997) 10: 111-112.
 7. *Pharmaceuticals* (1997) 10: 113-114.
 8. *Pharmaceuticals* (1997) 10: 115-116.
 9. *Pharmaceuticals* (1997) 10: 117-118.
 10. *Pharmaceuticals* (1997) 10: 119-120.
 11. *Pharmaceuticals* (1997) 10: 121-122.
 12. *Pharmaceuticals* (1997) 10: 123-124.
 13. *Pharmaceuticals* (1997) 10: 125-126.
 14. *Pharmaceuticals* (1997) 10: 127-128.
 15. *Pharmaceuticals* (1997) 10: 129-130.
 16. *Pharmaceuticals* (1997) 10: 131-132.
 17. *Pharmaceuticals* (1997) 10: 133-134.
 18. *Pharmaceuticals* (1997) 10: 135-136.
 19. *Pharmaceuticals* (1997) 10: 137-138.
 20. *Pharmaceuticals* (1997) 10: 139-140.
 21. *Pharmaceuticals* (1997) 10: 141-142.
 22. *Pharmaceuticals* (1997) 10: 143-144.
 23. *Pharmaceuticals* (1997) 10: 145-146.
 24. *Pharmaceuticals* (1997) 10: 147-148.
 25. *Pharmaceuticals* (1997) 10: 149-150.
 26. *Pharmaceuticals* (1997) 10: 151-152.
 27. *Pharmaceuticals* (1997) 10: 153-154.
 28. *Pharmaceuticals* (1997) 10: 155-156.
 29. *Pharmaceuticals* (1997) 10: 157-158.
 30. *Pharmaceuticals* (1997) 10: 159-160.
 31. *Pharmaceuticals* (1997) 10: 161-162.
 32. *Pharmaceuticals* (1997) 10: 163-164.
 33. *Pharmaceuticals* (1997) 10: 165-166.
 34. *Pharmaceuticals* (1997) 10: 167-168.
 35. *Pharmaceuticals* (1997) 10: 169-170.
 36. *Pharmaceuticals* (1997) 10: 171-172.
 37. *Pharmaceuticals* (1997) 10: 173-174.
 38. *Pharmaceuticals* (1997) 10: 175-176.
 39. *Pharmaceuticals* (1997) 10: 177-178.
 40. *Pharmaceuticals* (1997) 10: 179-180.
 41. *Pharmaceuticals* (1997) 10: 181-182.
 42. *Pharmaceuticals* (1997) 10: 183-184.
 43. *Pharmaceuticals* (1997) 10: 185-186.
 44. *Pharmaceuticals* (1997) 10: 187-188.
 45. *Pharmaceuticals* (1997) 10: 189-190.
 46. *Pharmaceuticals* (1997) 10: 191-192.
 47. *Pharmaceuticals* (1997) 10: 193-194.
 48. *Pharmaceuticals* (1997) 10: 195-196.
 49. *Pharmaceuticals* (1997) 10: 197-198.
 50. *Pharmaceuticals* (1997) 10: 199-200.
 51. *Pharmaceuticals* (1997) 10: 201-202.
 52. *Pharmaceuticals* (1997) 10: 203-204.
 53. *Pharmaceuticals* (1997) 10: 205-206.
 54. *Pharmaceuticals* (1997) 10: 207-208.
 55. *Pharmaceuticals* (1997) 10: 209-210.
 56. *Pharmaceuticals* (1997) 10: 211-212.
 57. *Pharmaceuticals* (1997) 10: 213-214.
 58. *Pharmaceuticals* (1997) 10: 215-216.
 59. *Pharmaceuticals* (1997) 10: 217-218.
 60. *Pharmaceuticals* (1997) 10: 219-220.
 61. *Pharmaceuticals* (1997) 10: 221-222.
 62. *Pharmaceuticals* (1997) 10: 223-224.
 63. *Pharmaceuticals* (1997) 10: 225-226.
 64. *Pharmaceuticals* (1997) 10: 227-228.
 65. *Pharmaceuticals* (1997) 10: 229-230.
 66. *Pharmaceuticals* (1997) 10: 231-232.
 67. *Pharmaceuticals* (1997) 10: 233-234.
 68. *Pharmaceuticals* (1997) 10: 235-236.
 69. *Pharmaceuticals* (1997) 10: 237-238.
 70. *Pharmaceuticals* (1997) 10: 239-240.
 71. *Pharmaceuticals* (1997) 10: 241-242.
 72. *Pharmaceuticals* (1997) 10: 243-244.
 73. *Pharmaceuticals* (1997) 10: 245-246.
 74. *Pharmaceuticals* (1997) 10: 247-248.
 75. *Pharmaceuticals* (1997) 10: 249-250.
 76. *Pharmaceuticals* (1997) 10: 251-252.
 77. *Pharmaceuticals* (1997) 10: 253-254.
 78. *Pharmaceuticals* (1997) 10: 255-256.
 79. *Pharmaceuticals* (1997) 10: 257-258.
 80. *Pharmaceuticals* (1997) 10: 259-260.
 81. *Pharmaceuticals* (1997) 10: 261-262.
 82. *Pharmaceuticals* (1997) 10: 263-264.
 83. *Pharmaceuticals* (1997) 10: 265-266.
 84. *Pharmaceuticals* (1997) 10: 267-268.
 85. *Pharmaceuticals* (1997) 10: 269-270.
 86. *Pharmaceuticals* (1997) 10: 271-272.
 87. *Pharmaceuticals* (1997) 10: 273-274.
 88. *Pharmaceuticals* (1997) 10: 275-276.
 89. *Pharmaceuticals* (1997) 10: 277-278.
 90. *Pharmaceuticals* (1997) 10: 279-280.
 91. *Pharmaceuticals* (1997) 10: 281-282.
 92. *Pharmaceuticals* (1997) 10: 283-284.
 93. *Pharmaceuticals* (1997) 10: 285-286.
 94. *Pharmaceuticals* (1997) 10: 287-288.
 95. *Pharmaceuticals* (1997) 10: 289-290.
 96. *Pharmaceuticals* (1997) 10: 291-292.
 97. *Pharmaceuticals* (1997) 10: 293-294.
 98. *Pharmaceuticals* (1997) 10: 295-296.
 99. *Pharmaceuticals* (1997) 10: 297-298.
 100. *Pharmaceuticals* (1997) 10: 299-300.
 101. *Pharmaceuticals* (1997) 10: 301-302.
 102. *Pharmaceuticals* (1997) 10: 303-304.
 103. *Pharmaceuticals* (1997) 10: 305-306.
 104. *Pharmaceuticals* (1997) 10: 307-308.
 105. *Pharmaceuticals* (1997) 10: 309-310.
 106. *Pharmaceuticals* (1997) 10: 311-312.
 107. *Pharmaceuticals* (1997) 10: 313-314.
 108. *Pharmaceuticals* (1997) 10: 315-316.
 109. *Pharmaceuticals* (1997) 10: 317-318.
 110. *Pharmaceuticals* (1997) 10: 319-320.
 111. *Pharmaceuticals* (1997

[illegible]

Figure 1. The effect of the initial concentration of the monomer on the polymerization of α -methylstyrene initiated by BuLi in THF at -78°C . The polymerization was carried out in the presence of 1.0×10^{-2} mole/l. of BuLi in THF at -78°C . The polymerization was terminated by the addition of methanol. The polymerization was carried out in the presence of 1.0×10^{-2} mole/l. of BuLi in THF at -78°C . The polymerization was terminated by the addition of methanol. The polymerization was carried out in the presence of 1.0×10^{-2} mole/l. of BuLi in THF at -78°C . The polymerization was terminated by the addition of methanol.